Re-resection for recurrent high-grade glioma in the setting of re-irradiation: more is not always better

Joshua D. Palmer, Joshua Siglin, Kosj Yamoah, Tu Dan, Colin E. Champ, Voichita Bar-Ad, Maria Werner-Wasik, James J. Evans, Lyndon Kim, Jon Glass, Christopher Farrell, David W. Andrews, Wenyin Shi

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The optimal treatment for patients with recurrent high grade glioma (HGG) remains controversial. Available therapies include surgery, re-irradiation, alternating electric fields or systemic therapy. Here we investigate whether re-resection will improve survival in patients receiving repeat radiotherapy for tumor recurrence. 231 consecutive patients with recurrent HGG treated with re-irradiation between 1994 and 2012 were analyzed. 105 patients underwent re-resection. Re-irradiation was delivered using daily fractions of 3.5 Gy to a median total dose of 35 Gy. Survival was then analyzed comparing patients with and without re-resection. Overall survival (OS) and survival from the first recurrence are reported. Univariate and cox-proportional hazard modeling was performed in a step-wise multivariate analysis using known prognostic factors. The median follow-up time from initial diagnosis was 25.7 months. The median OS from initial diagnosis of the entire group was 22.5 months. There was no significant difference in median overall survival between patients who received re-resection versus no re-resection, 23 versus 21.9 months respectively (p = 0.6). Additionally, there was no difference in median survival from the time of first recurrence 10.5 months without re-resection versus 11.1 months with re-resection (p = 0.09). After adjusting for known prognostic variables, only age remained significant. Re-irradiation is an effective salvage therapy for patients with localized, progressive high grade glioma, achieving a median survival of 10–11 months from re-irradiation. Our data reveals no significant improvement in survival with the addition of re-resection to re-irradiated patients with HGG.

Original languageEnglish (US)
Pages (from-to)215-221
Number of pages7
JournalJournal of Neuro-Oncology
Volume124
Issue number2
DOIs
StatePublished - Sep 29 2015

Fingerprint

Glioma
Survival
Recurrence
Re-Irradiation
Salvage Therapy
Radiotherapy
Therapeutics
Multivariate Analysis

Keywords

  • Fractionated stereotactic radiotherapy
  • Overall survival
  • Re-resection
  • Recurrent high-grade glioma

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

Re-resection for recurrent high-grade glioma in the setting of re-irradiation : more is not always better. / Palmer, Joshua D.; Siglin, Joshua; Yamoah, Kosj; Dan, Tu; Champ, Colin E.; Bar-Ad, Voichita; Werner-Wasik, Maria; Evans, James J.; Kim, Lyndon; Glass, Jon; Farrell, Christopher; Andrews, David W.; Shi, Wenyin.

In: Journal of Neuro-Oncology, Vol. 124, No. 2, 29.09.2015, p. 215-221.

Research output: Contribution to journalArticle

Palmer, JD, Siglin, J, Yamoah, K, Dan, T, Champ, CE, Bar-Ad, V, Werner-Wasik, M, Evans, JJ, Kim, L, Glass, J, Farrell, C, Andrews, DW & Shi, W 2015, 'Re-resection for recurrent high-grade glioma in the setting of re-irradiation: more is not always better', Journal of Neuro-Oncology, vol. 124, no. 2, pp. 215-221. https://doi.org/10.1007/s11060-015-1825-y
Palmer, Joshua D. ; Siglin, Joshua ; Yamoah, Kosj ; Dan, Tu ; Champ, Colin E. ; Bar-Ad, Voichita ; Werner-Wasik, Maria ; Evans, James J. ; Kim, Lyndon ; Glass, Jon ; Farrell, Christopher ; Andrews, David W. ; Shi, Wenyin. / Re-resection for recurrent high-grade glioma in the setting of re-irradiation : more is not always better. In: Journal of Neuro-Oncology. 2015 ; Vol. 124, No. 2. pp. 215-221.
@article{6efd9cec2e55440ab6d3728928d1a4f0,
title = "Re-resection for recurrent high-grade glioma in the setting of re-irradiation: more is not always better",
abstract = "The optimal treatment for patients with recurrent high grade glioma (HGG) remains controversial. Available therapies include surgery, re-irradiation, alternating electric fields or systemic therapy. Here we investigate whether re-resection will improve survival in patients receiving repeat radiotherapy for tumor recurrence. 231 consecutive patients with recurrent HGG treated with re-irradiation between 1994 and 2012 were analyzed. 105 patients underwent re-resection. Re-irradiation was delivered using daily fractions of 3.5 Gy to a median total dose of 35 Gy. Survival was then analyzed comparing patients with and without re-resection. Overall survival (OS) and survival from the first recurrence are reported. Univariate and cox-proportional hazard modeling was performed in a step-wise multivariate analysis using known prognostic factors. The median follow-up time from initial diagnosis was 25.7 months. The median OS from initial diagnosis of the entire group was 22.5 months. There was no significant difference in median overall survival between patients who received re-resection versus no re-resection, 23 versus 21.9 months respectively (p = 0.6). Additionally, there was no difference in median survival from the time of first recurrence 10.5 months without re-resection versus 11.1 months with re-resection (p = 0.09). After adjusting for known prognostic variables, only age remained significant. Re-irradiation is an effective salvage therapy for patients with localized, progressive high grade glioma, achieving a median survival of 10–11 months from re-irradiation. Our data reveals no significant improvement in survival with the addition of re-resection to re-irradiated patients with HGG.",
keywords = "Fractionated stereotactic radiotherapy, Overall survival, Re-resection, Recurrent high-grade glioma",
author = "Palmer, {Joshua D.} and Joshua Siglin and Kosj Yamoah and Tu Dan and Champ, {Colin E.} and Voichita Bar-Ad and Maria Werner-Wasik and Evans, {James J.} and Lyndon Kim and Jon Glass and Christopher Farrell and Andrews, {David W.} and Wenyin Shi",
year = "2015",
month = "9",
day = "29",
doi = "10.1007/s11060-015-1825-y",
language = "English (US)",
volume = "124",
pages = "215--221",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Re-resection for recurrent high-grade glioma in the setting of re-irradiation

T2 - more is not always better

AU - Palmer, Joshua D.

AU - Siglin, Joshua

AU - Yamoah, Kosj

AU - Dan, Tu

AU - Champ, Colin E.

AU - Bar-Ad, Voichita

AU - Werner-Wasik, Maria

AU - Evans, James J.

AU - Kim, Lyndon

AU - Glass, Jon

AU - Farrell, Christopher

AU - Andrews, David W.

AU - Shi, Wenyin

PY - 2015/9/29

Y1 - 2015/9/29

N2 - The optimal treatment for patients with recurrent high grade glioma (HGG) remains controversial. Available therapies include surgery, re-irradiation, alternating electric fields or systemic therapy. Here we investigate whether re-resection will improve survival in patients receiving repeat radiotherapy for tumor recurrence. 231 consecutive patients with recurrent HGG treated with re-irradiation between 1994 and 2012 were analyzed. 105 patients underwent re-resection. Re-irradiation was delivered using daily fractions of 3.5 Gy to a median total dose of 35 Gy. Survival was then analyzed comparing patients with and without re-resection. Overall survival (OS) and survival from the first recurrence are reported. Univariate and cox-proportional hazard modeling was performed in a step-wise multivariate analysis using known prognostic factors. The median follow-up time from initial diagnosis was 25.7 months. The median OS from initial diagnosis of the entire group was 22.5 months. There was no significant difference in median overall survival between patients who received re-resection versus no re-resection, 23 versus 21.9 months respectively (p = 0.6). Additionally, there was no difference in median survival from the time of first recurrence 10.5 months without re-resection versus 11.1 months with re-resection (p = 0.09). After adjusting for known prognostic variables, only age remained significant. Re-irradiation is an effective salvage therapy for patients with localized, progressive high grade glioma, achieving a median survival of 10–11 months from re-irradiation. Our data reveals no significant improvement in survival with the addition of re-resection to re-irradiated patients with HGG.

AB - The optimal treatment for patients with recurrent high grade glioma (HGG) remains controversial. Available therapies include surgery, re-irradiation, alternating electric fields or systemic therapy. Here we investigate whether re-resection will improve survival in patients receiving repeat radiotherapy for tumor recurrence. 231 consecutive patients with recurrent HGG treated with re-irradiation between 1994 and 2012 were analyzed. 105 patients underwent re-resection. Re-irradiation was delivered using daily fractions of 3.5 Gy to a median total dose of 35 Gy. Survival was then analyzed comparing patients with and without re-resection. Overall survival (OS) and survival from the first recurrence are reported. Univariate and cox-proportional hazard modeling was performed in a step-wise multivariate analysis using known prognostic factors. The median follow-up time from initial diagnosis was 25.7 months. The median OS from initial diagnosis of the entire group was 22.5 months. There was no significant difference in median overall survival between patients who received re-resection versus no re-resection, 23 versus 21.9 months respectively (p = 0.6). Additionally, there was no difference in median survival from the time of first recurrence 10.5 months without re-resection versus 11.1 months with re-resection (p = 0.09). After adjusting for known prognostic variables, only age remained significant. Re-irradiation is an effective salvage therapy for patients with localized, progressive high grade glioma, achieving a median survival of 10–11 months from re-irradiation. Our data reveals no significant improvement in survival with the addition of re-resection to re-irradiated patients with HGG.

KW - Fractionated stereotactic radiotherapy

KW - Overall survival

KW - Re-resection

KW - Recurrent high-grade glioma

UR - http://www.scopus.com/inward/record.url?scp=84942500077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942500077&partnerID=8YFLogxK

U2 - 10.1007/s11060-015-1825-y

DO - 10.1007/s11060-015-1825-y

M3 - Article

C2 - 26024653

AN - SCOPUS:84942500077

VL - 124

SP - 215

EP - 221

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 2

ER -